Tag Archives: Amag Pharmaceuticals

B.Riley FBR Believes Amag Pharmaceuticals (NASDAQ: AMAG) Still Has Room to Grow

In a report released today, David Buck from B.Riley FBR reiterated a Buy rating on Amag Pharmaceuticals (NASDAQ: AMAG), with a price target of $31. The company’s shares closed on Friday at $23.90, close to its 52-week high of $25.63.

Cantor Fitzgerald Sticks to Their Hold Rating for Amag Pharmaceuticals (AMAG)

In a report released today, William Tanner from Cantor Fitzgerald reiterated a Hold rating on Amag Pharmaceuticals (NASDAQ: AMAG), with a price target of $18. The company’s shares closed yesterday at $23.20. Tanner commented: “: We reiterate the Neutral rating

Amag Pharmaceuticals (AMAG) Gets a Hold Rating from Jefferies

In a report released yesterday, Eun Yang from Jefferies reiterated a Hold rating on Amag Pharmaceuticals (NASDAQ: AMAG), with a price target of $22. The company’s shares closed yesterday at $23.20. According to TipRanks.com, Yang is a 4-star analyst with

Amag Pharmaceuticals Gets a Buy Rating from B.Riley FBR

In a report released yesterday, David Buck from B.Riley FBR maintained a Buy rating on Amag Pharmaceuticals (NASDAQ: AMAG), with a price target of $30. The company’s shares opened today at $21.25. Buck noted: “This morning, 6/25, before market open,

Analysts Offer Insights on Healthcare Companies: Amag Pharmaceuticals (NASDAQ: AMAG) and Intercept Pharma (NASDAQ: ICPT)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amag Pharmaceuticals (NASDAQ: AMAG) and Intercept Pharma (NASDAQ: ICPT). Amag Pharmaceuticals (NASDAQ: AMAG) In a report released today, David Buck from B.Riley FBR

Amag Pharmaceuticals Receives a Hold from Piper Jaffray

In a report issued on February 27, Christopher Raymond from Piper Jaffray reiterated a Hold rating on Amag Pharmaceuticals (NASDAQ: AMAG), with a price target of $20. The company’s shares opened today at $20.90. According to TipRanks.com, Raymond is a